



Medicare Advantage Prostate Cancer Surveillance Quick Reference Guide (QRG)

Cigna has partnered with eviCore® to provide Radiation Therapy Services for your Medicare Advantage patients. eviCore's clinical guidelines have been carefully researched and are continually updated in order to be consistent with the most current evidence-based guidelines and recommendations for the provision of radiation therapy. To avoid potential authorization denials, please follow the QRG below for prostate cancer surveillance.

Surveillance/Follow-Up of Individuals with Low Risk Prostate Cancer on Active Surveillance Protocol

- Multiparametric Prostate MRI (CPT® 72197) no more often than every 12 months

Surveillance/Follow-Up of Individuals Previously Treated for Prostate Cancer – Indications below do not support advanced imaging

- Asymptomatic or stable chronic symptoms
- Stable DRE findings
- Stable PSA levels

Indications below support advanced imaging

- New or worsening symptoms
- Change in DRE findings
- Rising PSA

Any of the following can be approved

- CT Abdomen/Pelvis with contrast (CPT® 74177)
- MRI Pelvis without contrast (CPT® 72195) or without and with contrast (CPT® 72197)

Please contact our Client Services department at clientservices@evicore.com with any questions regarding the guidelines.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna HealthCare of South Carolina, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of Arizona, Inc., Cigna HealthCare of St. Louis, Inc., HealthSpring Life & Health Insurance Company, Inc., HealthSpring of Florida, Inc., Bravo Health Mid-Atlantic, Inc., and Bravo Health Pennsylvania, Inc. The Cigna name, logos, and other Cigna marks are owned by Cigna Intellectual Property, Inc.